Matthew De Silva

Endpoint Health is a Precision-First therapeutics company dedicated to addressing unmet needs in immune-mediated chronic and acute diseases. We leverage our proprietary artificial intelligence (AI) platform and combine companion diagnostics with therapeutics to develop precision therapies. Our vision is a world in which all patients get the best treatment possible for their unique biology and disease.

Builders believes it takes more than great technology to fix an antiquated industry. To truly make impactful change, Builders backs entrepreneurs who combine courage, technical acumen, and operational expertise. Transformative technology has never been more widely adopted than it has in the last decade, but to make lasting change, entrepreneurs will need more than innovative technology alone to unlock true value. Disruption doesn’t happen when a new algorithm is created. It happens when founders leverage technology and strong operational focus to address customer pain points, acquire customers, drive out inefficiencies, and unlock new business models. Builders is looking to work with founders focused on the intersection of great technology, antiquated industries, and operational excellence.

Endpoint Health is a Precision-First therapeutics company dedicated to addressing unmet needs in immune-mediated chronic and acute diseases. We leverage our proprietary artificial intelligence (AI) platform and combine companion diagnostics with therapeutics to develop precision therapies. Our vision is a world in which all patients get the best treatment possible for their unique biology and disease.

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community. Notable’s proprietary Predictive Precision Medicines Platform replicates ex vivo the clinical response of patients to cancer treatments with high fidelity, through its optimized integration of biological assay conditions, dynamic signal analysis, and AI-driven in-silico translation into predictive algorithms. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy and a fast-track clinical development approach that delivers a product’s medical impact and commercial value faster, higher, and more likely than traditional drug development.

Clarium Capital Management is an investment management firm that pursues a global macro strategy, seeking absolute returns through high conviction, directional investments based on key drivers of the global economy and fundamental themes underappreciated by the marketplace.